Vernalis and Asahi Kasei Pharma Achieve Research Milestone

Vernalis is pleased to announce the achievement of the second milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). Vernalis will receive a payment of £0.5m in recognition of this achievement.

This collaboration with AKP was initiated in October 2013 and utilises Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases. Overall financial terms of this collaboration have not been disclosed.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.